A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies
a study on Squamous Cell Carcinoma Merkel Cell Carcinoma Basal Cell Carcinoma Melanoma Skin Cancer/Melanoma Hematopoietic Cell Transplantation Carcinoma
- for people ages 18 years and up (full criteria)
- at UCLA UCSD UCSF
- study startedestimated completion
- Principal Investigator
- by Gregory Daniels, MD (ucsd)Wanxing Chai-Ho, MD (ucla)Katy Tsai, MD (ucsf)
Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Melanoma, Carcinoma, RP1, intra-tumoral injection, oncolytic virus
Lead Scientists at UC Cancer
- Gregory Daniels, MD (ucsd)
Dr. Daniels coordinates our clinical program in melanoma. His own research involves understanding the link between autoimmunity and tumor immunity in developing more effective and less toxic vaccines and immune stimulatory approaches for patients with melanoma.
- Wanxing Chai-Ho, MD (ucla)
HS Assistant Clinical Professor, Medicine. Authored (or co-authored) 7 research publications
- Katy Tsai, MD (ucsf)
Dr. Katy K. Tsai is a medical oncologist and clinical researcher who specializes in treating advanced melanoma and other non-melanoma skin cancers, such as squamous cell carcinoma, basal cell carcinoma, and Merkel cell carcinoma. Dr. Tsai graduated with a degree in comparative literature from Brown University before earning her medical degree from Brown.
- accepting new patients
- Start Date
- Completion Date
- Replimune Inc.
- Phase 1/2 research study
- Study Type
- Expecting 65 study participants
- Last Updated